Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy
Chen‐Han Chueh, Yi‐Wen Tsai, Zi-Rong Chen, Ming‐Neng Shiu, Yu‐Wen Wen, Nai-Jung Chiang
Topics & Concepts
RegimenIntrahepatic CholangiocarcinomaCost-effectiveness analysisMedicineHealth economicsOncologyInternal medicineCost effectivenessPublic healthActuarial scienceBusinessPathologyRisk analysis (engineering)Cholangiocarcinoma and Gallbladder Cancer StudiesFibroblast Growth Factor ResearchGastric Cancer Management and Outcomes